Last reviewed · How we verify
A Randomized Design Study to Compare the Efficacy of Pegylated Interferon Alpha-2b Monotherapy Versus Combination With Entecavir in HBeAg-negative Chronic Hepatitis B: Role of Host and Viral Factors Associated With Treatment Response
The outcome of treatment of chronic hepatitis B is determined by viral and host interaction, thus the combination therapy of immunomodulator (PEG-IFN) and potent antiviral drug (entecavir) should improve the response rate. In addition, the simultaneous assessment of viral and host genetic factors associated with SVR may help to identify predictors of treatment outcomes, which will in turn significant reduce the cost/effect of therapy
Details
| Lead sponsor | Chulalongkorn University |
|---|---|
| Phase | NA |
| Status | UNKNOWN |
| Enrolment | 126 |
| Start date | 2011-03 |
| Completion | 2013-12 |
Conditions
- Chronic Hepatitis B
Interventions
- PEG-IFN and entecavir
Primary outcomes
- To determine whether a combination of PEG-IFN and entecavir improves the rate of sustained response and HBsAg clearance in patients with HBeAg-negative chronic hepatitis B — 24 weeks post treatment
Countries
Thailand